Dr Anna Wilkins’ group is investigating how to target the tumour microenvironment of bladder and prostate cancer to prevent treatment resistance, especially to radiation given with curative intent.

Andrew joined the ICR initially as a post-doctoral scientist before moving to industry to work as a senior medicinal chemist. He re-joined ICR in March 2021 as a Medicinal Chemist in the Centre for ...